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Background
chizophrenia (SCZ) is a disease with an esti-
mated lifetime morbid risk approaching 1% worldwide,
1
and its public health consequences (mortality and mor-
bidity) are severe. SCZ is associated with an increase of
at least 50% in mortality rates compared with the gen-
eral population,
2 including a suicide rate of approxi-
mately 5%,
3 resulting in 10-year average lifespan reduc-
tion.
4 SCZ accounts for nearly 3% of all years lived with
disability
5; amongst individuals aged 15 to 44, SCZ is the
third-leading cause of disability.
6
Despite the demonstrated efficacy of antipsychotic drugs
(APDs) in short-term placebo-controlled clinical trials,
long-term outcomes frequently remain unsatisfactory. The
largest NIH-supported clinical trial of antipsychotic agents
conducted to date revealed that both first-generation
antipsychotics (FGAs) and second-generation antipsy-
chotic (SGA) agents have limited long-term effectiveness,
largely due to high rates of discontinuation (~75% dis-
continuation within 18 months).
7 Similar results were
obtained in two large-scale European effectiveness trials.
8,9
In each of these trials, clinically significant side effects were
noted in the majority of patients, and tolerability was the
primary cause of at least 20% of all drug discontinuations.
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Currently available antipsychotic drugs (APDs) carry sig-
nificant, though highly variable, liability to neurologic and
metabolic side effects. Pharmacogenetics approaches offer
the possibility of identifying patient-specific biomarkers
for predicting risk of these side effects. To date, a few sin-
gle nucleotide polymorphisms (SNPs) in a handful of genes
have received convergent support across multiple studies.
The primary focus has been on SNPs in dopamine and
serotonin receptor genes: persuasive meta-analytic evi-
dence exists for an effect of the dopamine D2 and D3
receptor genes (DRD2 and DRD3) in risk for tardive dysk-
inesia (TD) and for an effect of variation at the 5-HT2C
receptor gene (HTR2C) for liability to APD-induced weight
gain. However, effect sizes appear to be modest, and
pharmacoeconomic considerations have not been suffi-
ciently studied, thereby limiting clinical applicability at this
time. Effects of these genes and others on risk for TD,
extrapyramidal side effects, hyperprolactinemia, and
weight gain are reviewed in this article. 
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substantial clinical and economic implications, as treat-
ment nonadherence is perhaps the single strongest pre-
dictor of relapse and rehospitalization.
10 Patients who
have discontinued APDs may be as much as five times
more likely to relapse as medicated patients.
11 Moreover,
nearly half of rehospitalization costs in SCZ may be
accounted for by medication nonadherence.
12 In addition
to the effectiveness trials cited above, many observa-
tional studies and controlled trials have presented evi-
dence that perceived side-effect burden frequently leads
to both poor attitudes towards medications and a ten-
dency towards discontinuation, nonadherence, and par-
tial adherence.
13,14Although side effects are highly preva-
lent, there is also substantial variability in liability to
clinically significant or intolerable adverse events.
15
Consequently, understanding and predicting liability to
side effects may be an effective strategy to improve
prognosis in schizophrenia.
Antipsychotic-induced side effects
FGAs were most commonly associated with neuromus-
cular side effects, including the potentially irreversible
movement disorder, tardive dyskinesia (TD).
16 In large
cohort studies, TD has been shown to affect at least one
in five, and perhaps as many as one in three, patients
treated chronically with FGAs.
17 New onset (incidence)
of TD is approximately 3% to 5% per year of treatment,
and these rates are increased as much as fivefold in
elderly patients.
18 In addition to physical discomfort and
social stigma, presence of TD has been associated with
reduced quality of life, increased psychopathology, and
increased mortality rates.
19 Even at low doses and/or
intermittent treatment schedules, the high prevalence
and morbidity associated with TD was the primary
impetus for the promotion of SGAs as preferred first-
line treatment, at least in the United States.
15,20Although
use of SGAs is not entirely free from TD risk, incidence
and rates are as much as 80% lower for SGAs compared
with FGAs.
21,22
Though treatable and reversible, extrapyramidal symp-
toms (EPS) including Parkinsonian motor difficulties as
well as akathisia, are highly prevalent with FGAs and are
also associated with patient discomfort, dissatisfaction, and
discontinuation of treatment.
16 Despite the initial optimism
that SGAs would greatly reduce EPS burden, most SGAs
still demonstrate a clinically relevant tendency to induce
these symptoms.
23,24 In a large-scale effectiveness trial in
chronic SCZ patients, SGAs were indistinguishable from
a low-dose FGA (perphenazine) in rates of new onset of
akathisia and EPS (5% to 10% each, irrespective of drug
assignment).
25 However, meta-analytic reviews of the lit-
erature demonstrate that overall EPS burden may be
reduced by 30% to 50% with SGAs.
26 Because the mech-
anism of action for all currently approved antipsychotic
medications remains blockade of dopamine receptors,
27
motor and other side effects (eg, prolactin elevation)
remain a concern in the treatment of SCZ.
While SGAs have moderately reduced EPS and sub-
stantially reduced TD liability relative to FGAs, these
newer antipsychotics are most notable for their propen-
sity to induce weight gain,
28 as well as related metabolic
disturbances such as hypertriglyceridemia and hyper-
glycemia.
29 Clozapine and olanzapine are the APDs most
frequently associated with weight gain, but all APDs,
even first-generation agents, seem to share these effects
as a group to varying degrees.
30 For example, a large-
scale effectiveness trial in antipsychotic naïve patients
demonstrated clinically significant weight gain (≥7% of
baseline) in more than half of patients treated with
haloperidol.
9 Obesity has serious implications for over-
all health and survival due to an increased risk for car-
diovascular and malignant disorders
31; these risks may be
of particular importance in patients with SZ who often
have limited access to health care and decreased moti-
vation for weight reduction secondary to negative symp-
tomatology.
13 Unfortunately, APD-induced weight gain
is very difficult to reverse, even with sophisticated
behavioral, dietary, and pharmacological interventions.
32
Pharmacogenetic studies of 
antipsychotic-induced side effects
While the side effect profile of APDs is extremely bur-
densome in the aggregate, there is substantial interindi-
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Selected abbreviations and acronyms
5-HT serotonin
APD antipsychotic drug
EPS extrapyramidal symptom
FGA first-generation antipsychotic
SCZ schizophrenia
SGA second-generation antipsychotic
SNP single-nucleotide polymorphism
TD tardive dyskinesia
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or metabolic effect for a given patient.
15 Despite exten-
sive research over the last two decades, data on clini-
cal or biological predictors of antipsychotic side effects
are limited. A few generalizations can be made, but
these are not sufficient for individual-level prognosis:
i) both the very old and the very young appear to be
more susceptible to most APD-induced adverse
events
18,32; ii) patients experiencing extrapyramidal
symptoms are twice as likely to develop TD as patients
who do not exhibit EPS
33; iii) olanzapine and clozap-
ine have greater liability for metabolic effects and
reduced incidence of motoric side effects compared
with most other agents
7,9,26,30; iv) APD dose may be cor-
related with some of these effects, but the relationship
is weak and even low doses may carry substantial
risk.
16,17,32A priori identification of the patients who will
be at a higher risk for development of adverse side
effects could help clinicians avoid lengthy ineffective
APD trials and limit patients’ exposure to drug side
effects. 
Since the mid-1990s, the field of pharmacogenetics has
offered the potential for providing readily accessible,
immutable biomarkers—DNA sequence variants—that
might be predictive of an individual’s propensity for
both positive and adverse effects of drugs. However, to
date, the promise of personalized medicine has
remained unfulfilled. Because academic pharmacoge-
netic research is often limited to small and clinically het-
erogeneous samples, individual studies have been
unable to provide compelling results. Additionally, the
modest effect sizes which are common in complex
genetics present an obstacle in the quest for valid bio-
markers, which require high sensitivity and specificity
for individual clinical prediction. Moreover, examina-
tion of disparate polymorphisms across a wide variety
of candidate genes has created an impression of scat-
tered, unreplicated findings. Recently, however, a series
of findings across multiple laboratories have begun to
converge for a few genes related to serotonin and
dopamine, the most prominent neurotransmitters tar-
geted by APDs. In the subsequent sections, we will focus
on the converging evidence implicating the most well-
studied candidates for pharmacogenetic predictors of
antipsychotic-induced side effects. Particular emphasis
will be placed on single nucleotide polymorphisms
(SNPs) that have a sufficient evidence base to have per-
mitted published meta-analytic studies.
Tardive dyskinesia 
Tardive dyskinesia is the most extensively studied APD-
induced side effect in the pharmacogenetics literature to
date. These studies have typically been cross-sectional in
nature, with ascertainment based on retrospective iden-
tification of cases with varying treatment histories and
duration. The ability to study prevalence, rather than
incidence in the context of a clinical trial, has permitted
cumulative sample sizes in the thousands. It is important
to note, however, that this ascertainment strategy may
suffer from false negatives (patients with mild or
reversible TD) and false positives (patients with acute
motoric abnormalities that do not persist). Within this
literature, variants within the genes encoding dopamine
D2 and D3 receptors have been the primary focus, as
detailed below.
Dopamine D2 receptor blockade is a property of all
known antipsychotics, as demonstrated in vitro and in
vivo,
34 yet a predictive relationship between variation in
the DRD2 gene (located on chromosome 11q22) and
APD-induced side effects has only been examined in a
handful of studies. Most pharmacogenetic studies to
date have examined the 3’ Taq1A polymorphism
(rs1800497), which more recently has been determined
to be a nonsynonymous coding SNP in a neighboring
ankyrin repeat gene (ANKK1 Glu713Lys).
35 Possibly
due to linkage disequilibrium with another site (or sites)
within DRD2 (Figure 1), the minor (T) allele (also
called the A1 allele) at rs1800497 has been associated
with a 40% reduction in striatal D2 receptor density
based on both in vitro assays
36 and in vivo imaging stud-
ies.
37This allele appears to be protective against TD. As
shown in Table I, two recent meta-analyses (based on
overlapping sets of studies) have persuasively demon-
strated increased rates of TD in A2 (C) allele carri-
ers.
38,39 The odds ratio (OR) of 1.30 indicates a 30%
increase in risk for TD per allele, so that A2/A2 homozy-
gotes are nearly 80% more likely to develop TD as
A1/A1 homozygotes. Alternately, it can be said that
A1/A1 homozygotes have nearly half the rate of TD
compared with A2/A2 homozygotes. However, it is
important to note that the A2 allele is the common
allele at this SNP, and A1/A1 homozygotes represent
<10% of the Caucasian population (A1 allele frequen-
cies are much higher in non-white populations).
Like the D2 receptor, the dopamine D3 receptor is also
selectively expressed in the basal ganglia and is consid-
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45; conse-
quently, several pharmacogenetic studies in schizophre-
nia have examined the DRD3 gene, located on chromo-
some 3q13.3. To date, only one functional SNP (rs6280),
a missense variant resulting in a Ser to Gly substitution
at amino acid position 9, has been validated for DRD3.
46
The Gly variant has about a 35% allele frequency in
non-African populations, and is actually the ancestral
allele. The Gly variant has been associated with 4-fold
greater dopamine binding affinity in vitro,
47 resulting in
increased dopamine-mediated cAMP response and pro-
longed mitogen-associated protein kinase (MAPK) sig-
nal.
48 Several studies
49-52 (but not all)
53,54 have indicated
that subjects carrying the Gly variant exhibit enhanced
symptom response to treatment with clozapine or
risperidone.
Concordant with the finding of heightened dopaminer-
gic sensitivity for the Gly allele, multiple studies have
demonstrated a significant increase in risk for tardive
dyskinesia (TD) amongst Gly carriers. Despite several
Pharmacological aspects
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Figure 1. Location of the Taq1A polymorphism in the context of ANKK1 and DRD2 at chromosome 11q22. Red triangles represent areas of high
linkage equilibrium (D’). 
Gene SNP  Allele No of studies N patients (with /without TD) OR Reference
DRD2 Taq1A (rs1800497) A2 (C) 6 1256 (507/749) 1.30 Zai et al 2007
38
DRD2 Taq1A (rs1800497) A2 (C) 4 764 (297/467) 1.30 Bakker et al 2008
39
DRD3 Ser9Gly (rs6280) Gly(C) 8 780 (317/463) 1.33 Lerer et al 2002
40
DRD3 Ser9Gly (rs6280) Gly(C) 11 1610 (695/915) 1.17 Bakker et al 2006
41
DRD3 Ser9Gly (rs6280) Gly(C) 13 2026(928/1098) 1.16 Tsai et al 2009
42
COMT Val158Met (rs4680) Val(G) 5 1089 (382/707) 1.19 Bakker et al 2008
39
HTR2A T102C (rs6313) C 6 635 (256/379) 1.64 Lerer et al 2005
43
CYP2D6 Loss of function alleles 8 569 (220/349) 1.43 Patsopoulos 2005
44
SOD2 Ala9Val (rs4880) Ala(T) 4 680 (134/546) 2.04 Bakker et al 2008
39
Table I. List of meta-analytic studies of single nucleotide polymorphisms (SNPs) from candidate genes for tardive dyskinesia (TD), with the associ-
ated allele and odds ratio (OR) of the association.
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negative studies in the literature, three recent meta-ana-
lytic studies
40-42 indicate that this effect is detectable
across a large pooled sample including patients of mul-
tiple ethnicities (Table I). Intriguingly, a recent study
indicates a strong association of the Gly allele with
familial essential tremor, the most common inherited
movement disorder.
48 However, the effect size for TD
risk is modest (OR=1.16 in the largest meta-analysis),
with diminishing effects in the more recent studies of
this SNP. This pattern of diminishing effect size estimates
over time, termed “the winner’s curse,” is common in
genetics studies and can ultimately result in rejection of
the initial finding as a false positive.
55 It is notable that
this phenomenon was observed in the context of 13 pub-
lished studies of DRD3 Ser9Gly. Moreover, a very recent
study in the large CATIE cohort (n=207 cases with TD
vs 503 cases without TD), which was not included in any
meta-analysis, demonstrated essentially no effects of
either DRD3 Ser9Gly or DRD2Taq1A.
56Therefore, cau-
tion is warranted in the interpretation of other relation-
ships reported across much smaller study sets.
A third dopamine-related gene that has been investigated
in multiple pharmacogenetic studies of TD is Catechol O-
methyltransferase (COMT). While subcortical dopamine
activity is primarily terminated by reuptake mediated by
the dopamine transporter, a secondary mechanism for
dopamine clearance is metabolic degradation via COMT.
57
Additionally, COMT is the predominant mechanism of
dopamine clearance in frontal cortex. The COMT gene
contains a functional polymorphism that codes for a sub-
stitution of methionine (met) for valine (val) at codon 158.
The met allele, which has 36% to 48% allele frequency
across various ethnicities, results in a thermolabile protein
that has one fourth the enzymatic activity of the val car-
rying protein.
58 (In other words, the val allele results in
reduced synaptic dopamine due to more rapid clearance).
Across five studies meta-analyzed by Bakker and col-
leagues,
39 the val allele was associated with modestly
increased risk for TD (OR=1.19; Table I). It is unknown
whether the protective effect of the met allele is a direct
result of subcortical COMT activity, or is secondary to
alterations (eg, upregulation) in frontostriatal circuitry. 
In addition to dopamine antagonism, one of the common
features of many antipsychotics is near-saturation bind-
ing of serotonin (5-HT)2 receptors, which has been con-
firmed in vivo using PET imaging.
59,60While 5-HT binding
is often considered a hallmark of SGAs, it is important to
note that serotonergic binding properties are observed for
several FGAs as well.
61,62 The 5-HT2A receptor gene
(HTR2A) has been examined in several pharmacogenetic
studies of TD; in particular, a promoter region SNP
(rs6313), which has been previously associated with
response to antipsychotics (as well as antidepressants), has
been extensively studied in relation to TD. While these
studies generally converge to indicate a modestly reduced
effect of the C allele on symptom response,
63 this same
allele has been associated with significantly increased risk
for tardive dyskinesia.
43 As shown in Table I, a recent
meta-analysis reported an odds ratio of about 1.6 for C
allele carriers across 6 studies; effects were strongest in
older patients (age >47 years), and were specifically asso-
ciated with limb-truncal (but not orofacial) TD.
43 Notably,
this SNP is a perfect proxy for another promoter region
SNP, rs6311 (also referred to as -1438G/A), which appears
to affect transcription of the receptor.
64 Specifically, the G
allele (a perfect proxy for the C allele at rs6313) tends to
be associated with reduced expression of the receptor. It
can therefore be inferred that reduced availability of the
5-HT2A receptor is a risk factor for tardive dyskinesia.
Notably, 5-HT2A receptors are strongly expressed in the
caudate and putamen,
65 and recent evidence obtained
from dopamine-depleted rodents suggests a complex
interplay of subcortical dopamine and 5-HT in the regu-
lation of motor behavior.
66
Two genes outside of the dopamine and 5-HT systems
have received sufficient attention in the pharmacoge-
netics of TD to merit meta-analysis (Table I). Many com-
monly prescribed APDs, including FGAs (haloperidol,
perphenazine, thioridazine), as well as SGAs (risperidone
and aripiprazole), are metabolized in the liver by
CYP2D6 (debrisoquine hydroxylase).
67 The CYP2D6
gene is highly polymorphic, with over 70 known variants
(for a current classification, view the allele nomenclature
at http://www.imm.ki.se/CYPalleles/). Homozygosity for
null alleles gives rise to the “poor metabolizer” pheno-
type characterized by no enzyme activity while null allele
heterozygosity gives rise to an intermediate debrisoquine
hydroxylase metabolic phenotype characterized by
impaired—but not absent—enzyme activity.
68 Reduced
CYP2D6 activity can be expected to result in higher
effect dose as measured by blood levels of active drug,
with potential for increased dose-dependent side effects.
Consistent with this pharmacokinetic prediction, a meta-
analysis of 8 studies demonstrated a moderate effect of
(any) loss of function alleles on risk for TD (OR=1.43),
while homozygotes (poor metabolizers) had 1.64-fold
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44A recent
small study further confirms these results.
69 A similar
effect has been studied for SOD2, the gene encoding
manganese superoxide dismutase, a mitochondrial
enzyme involved in oxidative metabolism. A functional
SNP (Ala9Val), affecting efficiency of MnSOD transport,
has been associated with TD risk; counterintuitively, the
less efficient val allele is protective.
39 Homozygotes for
the Ala (T) allele are about twice as likely to develop TD
compared with val carriers (Table I).
Extrapyramidal symptoms
Compared with the relative plethora of studies on tar-
dive dyskinesia, pharmacogenetic studies of EPS are
lacking. However, a few studies have reported allelic
effects on acute side effects that are consistent with
those reported for TD. For example, Eichammer et al
70
reported increased incidence of akathisia amongst
DRD3 Gly carriers; however, two studies of extrapyra-
midal symptoms have been negative.
71,72 One additional
study identified another DRD3 SNP (rs167771) which
was associated with EPS in a study of 270 risperidone-
treated patients,
73 but this result awaits replication. One
small study has demonstrated an effect on EPS risk for
the C allele of rs6313 in HTR2A that parallels its effect
on TD.
71Although not previously examined in TD stud-
ies, a SNP in RGS2 (rs4606) has been associated with
extrapyramidal symptoms in two studies.
74,75 Although
a third study was negative, this regulator of intracellular
dopamine signaling merits additional research.
76
Prolactin elevation 
While prolactin elevation has also not been widely studied
across most of the genes listed in Table I, there have been
seven published studies examining DRD2Taq1A.
77-83As
displayed in Table II, these studies have yielded mixed
results across a variety of APDs. Notably, the three pos-
itive studies all reported that the A1 allele was associ-
ated with increased risk for hyperprolactinemia, and a
fourth study demonstrated the same effect in females
only. This is the opposite allele that was associated with
TD, which may reflect the fact that prolactin response is
mediated via the tuberoinfundibular pathway (hypo-
thalamus and pituitary).
84
Weight gain
It has been suggested that increased 5-HT binding pro-
files may account for the increased liability to weight
gain observed in the second-generation antipsychotics.
85
A survey of the literature of the regulation of feeding
behavior points to a major role for 5-HT, with both ani-
mal and human investigations showing, in general, that
increasing 5-HT results in decreased feeding, with the
reverse also true.
86 Pharmacologic agonists of 5-HT2C
lead to decreased feeding in animals
87 it is logical to spec-
ulate that 5-HT2C antagonists, including most second-
generation antipsychotics, might lead to increased food
intake. 
Perhaps the best evidence for a specific role of sero-
tonin-related genetic factors in antipsychotic–induced
weight gain is provided by studies of the promoter
region polymorphism, -759 T/C (rs3813929), in the
HTR2C gene (on the X chromosome). Reynolds and
colleagues
88 studied 123 adult drug-naïve Han Chinese
SCZ patients treated primarily with risperidone or
chlorpromazine. Subjects with the T allele at this locus
gained significantly less weight than subjects with the
C allele in short-term (6- and 10-week) treatment; none
of the 27 subjects with the T allele met criteria for
severe (>7%) weight gain after 6 weeks, as compared
with 28% of the 96 subjects without the T allele. Two
Pharmacological aspects
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Reference Drug N patients Allele Significant?
Calarge et al 2009
77 Risperidone 107 A1 (T) Yes
Kwon et al 2008
78 Aripiprazole 90 No
Yasui-Furukori et al 2008
79 Risperidone 174 No
Aklillu et al 2007
80 Perphenazine 22 A1 (T) Yes
Anderson et al 2007
81 Risperidone 101 No
Young et al 2004
82 Various 144 A1 (T) Yes
Mihara et al 2000
83 Nemonapride 25 A1 (T) Females only
Table II. List of studies of the Taq1A polymorphism (rs1800497) from the ANKK1/DRD2 locus in association with antipsychotic drug-related prolactin
levels. 
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89,90 also reported an association of the T allele to
reduced weight gain in a small samples of clozapine-
treated patients, although this effect was only signifi-
cant in males in one of these. Ellingrod and colleagues
91
reported that the T allele is associated with less weight
gain in Caucasian patients treated with olanzapine, and
Templeman et al
92 reported the same for weight gain
associated with a mixed group of antipsychotics in a
small Spanish first-episode cohort. Recently, Lane et
al
93 extended these findings to include risperidone (in
123 Han Chinese inpatients), and Ryu et al
94 demon-
strated the same effect for the T allele in 84 Korean
inpatients treated on various antipsychotic monother-
apies. A few studies, however, have not detected sig-
nificant associations between–759 T/C and clozapine-
induced weight gain
95-97 which may reflect the winner’s
curse, but it should be noted that these studies were
restricted to chronic patients with extensive prior treat-
ment. A meta-analysis of 8 studies demonstrated a
greater than 2-fold increase in risk for clinically signif-
icant (7% to 10% or greater) weight gain from baseline
associated with the C allele at this SNP.
98
Analogous to the aforementioned role of RGS2 in EPS,
one gene involved in intracellular signaling has been
repeatedly with respect to APD-induced weight gain.
GNB3 encodes a subunit of a heterotrimeric guanine
nucleotide-binding protein (G protein), which integrates
signals between receptors and effector proteins.
99An SNP
polymorphism (C825T) in this gene has been associated
with essential hypertension and obesity; this SNP is also
associated with relative prevalence of a high-activity splice
variant of GNB3.
100According to a recent meta-analysis,
five studies have examined effects of this SNP on APD-
induced weight gain; the T allele was marginally associated
with increased weight gain.
101 However, this effect was con-
sistent with its effect on BMI and other metabolic vari-
ables in the general population, so the mechanism in the
context of APD treatment remains unclear.
Conclusions and future directions
As summarized in the preceding sections, pharmacoge-
netic studies have begun to converge on a few genetic
variants that are replicably associated with the common
APD-induced motor and metabolic side effects.
However, three factors limit the ability of the field to
deliver on the promise of personalized medicine at this
time, and point to critical issues for the next generation
of pharmacogenetic studies. First, a treating psychiatrist
would be unable to use this information to offer a vali-
dated alternative, due to the lack of pharmacogenetic
head-to-head comparisons of treatment with differing
mechanisms. Second, even fairly consistent single-gene
results, such as those observed for DRD3 and TD, fail to
provide large enough effect sizes to make confident clin-
ical decisions. In order to provide a clinically useful test,
with sufficient sensitivity and specificity to make confi-
dent individual predictions, a combination of SNPs
across different loci will be required. Third, the eco-
nomics of conducting pharmacogenetic tests on a large
clinical scale will need to be justified to payers, includ-
ing the insurance companies and the federal govern-
ment. In order to do so, pharmacogenetics researchers
will need to quantify the beneficial economic impact of
tailored prescription practices.
102
Of course, any personalized clinical decision-making
process will optimally include validated predictors of
symptom response as well as adverse effects. The vari-
ability in symptom response ranges from patients who
experience rapid symptom remission to a subset of
patients often described as “treatment-refractory.”
15
Even when fully adherent with medication, as many as
40% of patients fail to demonstrate adequate response
on the hallmark positive symptoms of hallucinations and
delusions.
103 Unfortunately, the literature on pharmaco-
genetics of response is more difficult to summarize than
for side effects; due to wide differences in trial method-
ology and definition of dependent measures, no meta-
analytic studies have been published in the last decade.
(One early meta-analysis of clozapine response identi-
fied an effect of HTR2CT102C, as described earlier.
61) 
Finally, it should be noted that candidate gene
approaches to pharmacogenetics run a dual risk of either
an overly restrictive search space, or a potentially over-
whelming number of candidates. While initial pharma-
cogenetic studies have primarily focused on dopamine
and serotonin genes, the slow pace of individual candi-
date gene investigations has resulted in many additional
scattered and isolated studies across investigators. On
the other hand, the advent of genome-wide association
studies (GWAS) provides a hypothesis-free method of
generating candidate genes for novel complex pheno-
types. Unfortunately, this method carries its own statis-
tical concerns, most notably limitations in statistical
power (due to correction for multiple comparisons) in
necessarily limited clinical trial samples. 
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the short run is to utilize a strategy that permits cross-
sectionally defined phenotypes. In a proof of principle
study, we have recently utilized the Affymetrix 500K
microarray in a sample of our retrospectively-charac-
terized patients with schizophrenia. (Initial case-control
analyses were SCZ diagnosis were published for data
obtained from the first 322 Caucasian subjects.
104All sub-
jects self-identified as Caucasian non-Hispanic; testing
of 210 ancestry informative markers (AIMs) revealed no
evidence of population stratification). In this same sam-
ple, we have performed a preliminary analysis examin-
ing treatment responsiveness, using clozapine assign-
ment as a proxy for poor response. Detailed chart
reviews permitted classification of 97% of the sample.
Approximately 35% of patients were assigned clozapine
due to treatment nonresponsiveness, and groups were
matched on key demographic variables including age,
duration of illness, sex, and family history. Despite the
small sample for this interim analysis, one SNP nearly
obtained genome-wide significance (P=4.3*10-7). This
SNP neighbors CNTN4 (contactin-4), a neuronal mem-
brane protein that functions as a cell adhesion molecule,
and is thought to be critical for the formation of axon
connections in the developing nervous system
105; CNTN4
has also recently been implicated in autism.
106
In the longer term, much larger prospective studies will
be required to achieve to: i) obtain clear estimates for
risk parameters; and ii) determine whether application
of a pharmacogenetic risk profile is clinically and eco-
nomically advantageous. Optimally, such studies may
focus on the first episode of SCZ, which typically occurs
in late adolescence or early adulthood
107 and may be the
most critical period in the life of an individual with SCZ.
Successful treatment of the initial psychotic episode is
crucial for minimizing the cascading effects of social and
vocational deterioration.
108,109 From a methodological per-
spective, studies of first-episode patients minimize poten-
tial confounds associated with chronic illness and vari-
able history of prior treatment; first-episode cohorts are
also marked by reduced duration of psychotic symptoms,
substance abuse, and functional/social disabilities.
110 By
contrast, studies of chronic SCZ may systematically over-
represent patients who are not fully responsive to treat-
ment or are nonadherent to treatment (or both), and
underestimate APD response. First-episode samples may
be less biased on these factors and therefore may be
more informative about the spectrum of outcomes with
APD treatments. While large-scale prospective trials
involving first-episode cohorts are logistically challeng-
ing, such studies would hold substantial promise for
advancing the field in the next decade. ❏
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